Genprex, Inc.
GNPX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.81
KIRA · Stoqly’s AI analyst, in plain words
- Genprex, Inc. lost $16.2M in fiscal 2025.
Market cap
—
P/E
—
Revenue
—
Net income
−$16.2M
Free cash flow
—
Operating margin
—
Genprex, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$16.2M
No. It lost money last year.
What Genprex, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Genprex, Inc.
- CIK
- 0001595248
Genprex, Inc. · GNPX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Net income | −$20.7M | −$23.7M | −$30.9M | −$21.1M | −$16.2M |
| Diluted EPS | −$0.42 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$14.3M | −$17.6M | −$24.7M | −$17.9M | −$15.3M |
| Capital expenditure | $0.0M | $0.0M | — | — | — |
| Free cash flow | −$14.3M | −$17.6M | — | — | — |
| Share count change | 32.6% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $38.6M | $21.0M | $6.7M | $1.6M | $7.8M |
| Shareholders' equity | $41.3M | $22.3M | $7.4M | $1.6M | $8.0M |
| Current ratio | 24.7x | 7.6x | 2.3x | 0.8x | 3.8x |
| Returns and quality | |||||
| Return on equity | −57.2% | −74.7% | −207.9% | −467.2% | −338.7% |
| Return on tangible equity | −50.9% | −110.0% | −464.6% | −1,320.1% | −203.8% |
| Piotroski F-score | 2 | — | — | — | — |
| Altman Z'' | 23.8 | −6.5 | −55.4 | −156.9 | −57.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Genprex, Inc. · GNPX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.81 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001595248). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.